FDA Approves Orforglipron Under CNPV
The FDA announced the approval of Foundayo (orforglipron), the first new molecular entity approved through the Commissioner’s National Priority Voucher (CNPV) pilot program.
The FDA indicated Foundayo is approved for long-term reduction and maintenance of weight reduction in adults with obesity, or adults with overweight who have at least one weight-related comorbid condition, used with a reduced-calorie diet and increased physical activity. The agency cited two randomized, double-blind, placebo-controlled trials in these populations as the basis for approval. Across the trials, 72 weeks of treatment with Foundayo was associated with a statistically significant reduction in body weight compared with placebo.
Foundayo is an oral glucagon-like peptide-1 receptor agonist tablet taken once daily, with dosing that begins at 0.8 mg and may be escalated to 2.5 mg after at least 30 days and to 5.5 mg after another 30 days. The labeling also notes optional further increases to 9 mg, 14.5 mg, or 17.2 mg after at least 30 days at each level based on treatment response and tolerability.
Common adverse reactions include nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, burping, gastroesophageal reflux disease, gas, and hair loss. The labeling includes a boxed warning for thyroid C-cell tumors and additional warnings and precautions, and it stated the product should not be used with another GLP-1 receptor agonist.
Frequently Asked Questions
What's the latest on GLP-1 receptor agonists for obesity and weight management?
On April 7, 2026, the FDA approved Foundayo (orforglipron), an oral, once-daily glucagon-like peptide-1 receptor agonist tablet, for long-term reduction and maintenance of weight reduction in adults with obesity, or adults with overweight who have at least one weight-related comorbid condition, used with a reduced-calorie diet and increased physical activity. It is the first new molecular entity approved under the FDA's Commissioner's National Priority Voucher (CNPV) pilot program. Approval was based on two randomized, double-blind, placebo-controlled trials in which 72 weeks of treatment was associated with a statistically significant reduction in body weight compared with placebo.
What's new in obesity medicine for primary care?
The orforglipron approval introduces the first oral GLP-1 receptor agonist tablet for chronic weight management — a meaningful change for primary care, where injectable GLP-1 receptor agonists have to date been the predominant option. Dosing begins at 0.8 mg once daily and may be escalated to 2.5 mg after at least 30 days, then to 5.5 mg after another 30 days, with optional further increases to 9 mg, 14.5 mg, or 17.2 mg after at least 30 days at each level based on response and tolerability. The indication is restricted to adults with obesity or adults with overweight plus at least one weight-related comorbid condition, in combination with diet and physical activity.
Where can I find free CME on hot clinical topics like obesity drugs and GLP-1s?
ReachMD's Advances in Obesity Management Learning Center hosts free, accredited CME on obesity pharmacotherapy, including GLP-1 receptor agonists and newer incretin-based therapies. The Endocrinology CME hub aggregates additional accredited education on diabetes and obesity medicine. Both are accessible without charge after free ReachMD registration: Advances in Obesity Management and Endocrinology CME.
What are the safety findings and warnings for orforglipron?
Common adverse reactions reported in the labeling include nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, burping, gastroesophageal reflux disease, gas, and hair loss. The labeling includes a boxed warning for thyroid C-cell tumors, additional warnings and precautions, and a statement that the product should not be used with another GLP-1 receptor agonist.
Who is orforglipron approved for, and who should not receive it?
Orforglipron is approved for adults with obesity, or adults with overweight who have at least one weight-related comorbid condition, used together with a reduced-calorie diet and increased physical activity. It should not be used concomitantly with another GLP-1 receptor agonist. The boxed warning for thyroid C-cell tumors and other labeled warnings should be reviewed before prescribing. The two pivotal trials supporting approval enrolled adults in these populations; applicability to other populations or to use outside the labeled indication is not established by the approval data.